Skip to main content
. Author manuscript; available in PMC: 2021 May 19.
Published in final edited form as: Leukemia. 2019 Aug 22;34(1):35–49. doi: 10.1038/s41375-019-0531-8

Fig. 4.

Fig. 4

Anti-IL-7Rα controls the growth of patient- derived T-ALL xenografts in NOD. SCID mice. a Experimental protocol. Patient derived T-ALL xenografts were established by intravenous injection in NOD. SCID mice on day 0. Mice were given weekly injections of anti-IL-7Rα or isotype control beginning on day 1 for a total of 11 injections. b Reduction of leukemia burden in the peripheral blood of a subset of treated mice (n = 2–3) compared to isotype treated controls (n = 2–3). c Kaplan Meier curve depicting survival prolongation in xenografts by anti-IL-7Rα 4A10 (treated; n = 7) compared to isotype control treated mice (control; n = 6). One mouse that did not develop leukemia was excluded from the control group. Survival analysis by Log-rank (Mantel-Cox) test. d Leukemia burden in the bone marrow by anti-hIL7Rα 4A10 (treated) at D33, compared to isotype control treated mice. Leukemia burden was determined by flow cytometry using antibodies specific for human CD45. Bars represent mean values and n = 3 for both groups